We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Immunome (IMNM) Moves 13.3% Higher: Will This Strength Last?
Read MoreHide Full Article
Immunome, Inc. (IMNM - Free Report) shares rallied 13.3% in the last trading session to close at $21.87. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 13.1% loss over the past four weeks.
Immunome’s stock price rally is largely tied to the renewed investor optimism around its advancing oncology pipeline, particularly continued momentum from its lead asset varegacestat and broader clinical progress. The company has reported strong phase III data for varegacestat in desmoid tumors, with plans for a potential FDA filing in 2026. Investors are also encouraged by Immunome’s expanding pipeline, including IM-1021 and several ADC programs, which offer promising long-term growth potential.
This company is expected to post quarterly loss of $0.60 per share in its upcoming report, which represents a year-over-year change of -15.4%. Revenues are expected to be $2 million, down 31.7% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Immunome, the consensus EPS estimate for the quarter has been revised 7.6% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on IMNM going forward to see if this recent jump can turn into more strength down the road.
Immunome is part of the Zacks Medical - Biomedical and Genetics industry. CytomX Therapeutics (CTMX - Free Report) , another stock in the same industry, closed the last trading session 6.6% higher at $4.7. CTMX has returned -17.4% in the past month.
CytomX Therapeutics' consensus EPS estimate for the upcoming report has changed -44.9% over the past month to -$0.14. Compared to the company's year-ago EPS, this represents a change of -151.9%. CytomX Therapeutics currently boasts a Zacks Rank of #3 (Hold).
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Immunome (IMNM) Moves 13.3% Higher: Will This Strength Last?
Immunome, Inc. (IMNM - Free Report) shares rallied 13.3% in the last trading session to close at $21.87. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 13.1% loss over the past four weeks.
Immunome’s stock price rally is largely tied to the renewed investor optimism around its advancing oncology pipeline, particularly continued momentum from its lead asset varegacestat and broader clinical progress. The company has reported strong phase III data for varegacestat in desmoid tumors, with plans for a potential FDA filing in 2026. Investors are also encouraged by Immunome’s expanding pipeline, including IM-1021 and several ADC programs, which offer promising long-term growth potential.
This company is expected to post quarterly loss of $0.60 per share in its upcoming report, which represents a year-over-year change of -15.4%. Revenues are expected to be $2 million, down 31.7% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Immunome, the consensus EPS estimate for the quarter has been revised 7.6% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on IMNM going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Immunome is part of the Zacks Medical - Biomedical and Genetics industry. CytomX Therapeutics (CTMX - Free Report) , another stock in the same industry, closed the last trading session 6.6% higher at $4.7. CTMX has returned -17.4% in the past month.
CytomX Therapeutics' consensus EPS estimate for the upcoming report has changed -44.9% over the past month to -$0.14. Compared to the company's year-ago EPS, this represents a change of -151.9%. CytomX Therapeutics currently boasts a Zacks Rank of #3 (Hold).